The neuromodulation market size has grown rapidly in recent years. It will grow from $7.62 billion in 2025 to $8.45 billion in 2026 at a compound annual growth rate (CAGR) of 10.9%. The growth in the historic period can be attributed to rising prevalence of chronic pain conditions, growing incidence of neurological disorders, increased acceptance of minimally invasive therapies, expansion of specialized pain management centers, availability of advanced implantable devices.
The neuromodulation market size is expected to see rapid growth in the next few years. It will grow to $12.88 billion in 2030 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to increasing adoption of ai-assisted neuromodulation systems, rising demand for home-based neuromodulation therapies, expansion of indications in psychiatric and neurological disorders, growing focus on patient-specific stimulation protocols, continuous technological advancements in biomaterials and device miniaturization. Major trends in the forecast period include increasing adoption of implantable neuromodulation devices, rising use of non-invasive neuromodulation therapies, growing integration of smart and programmable stimulators, expansion of neuromodulation applications beyond pain, enhanced focus on personalized neurotherapy.
Increasing healthcare expenditures are projected to drive the growth of the neuromodulation market in the coming years. Healthcare expenditure encompasses the total funds allocated for health care and related activities, including health services provision, public and private health insurance, health research, and public health initiatives. Rising expenditures support the development and adoption of new therapies and diagnostic methods for neurological disorders, and they also provide additional funding for research into innovative neuromodulation technologies, enhancing their efficacy, safety, and targeting capabilities. For example, in June 2025, according to the Centers for Medicare & Medicaid Services, national health expenditures in 2023 increased by 7.5% to reach $4.9 trillion, or $14,570 per capita, representing 17.6% of the United States gross domestic product. Thus, the rising healthcare expenditure is fueling the growth of the neuromodulation market.
Leading players in the neuromodulation sector are prioritizing the development of next-generation solutions, including advanced implantable pulse generators (IPGs), to enhance therapeutic accuracy, improve patient comfort, and strengthen their competitive positioning. An IPG is a small, battery-powered device implanted beneath the skin commonly in the chest or abdominal area, that delivers controlled electrical stimulation to treat neurological disorders. Ongoing innovations focus on enabling greater personalization, extending battery life, and simplifying implantation procedures. For instance, in July 2023, Boston Scientific Corporation received approval from the U.S. Food and Drug Administration for its Vercise Neural Navigator 5 software with STIMVIEW XT technology, intended for use with the fourth-generation Vercise Genus Deep Brain Stimulation system. The solution supports both rechargeable and non-rechargeable IPGs and accommodates five magnetic resonance-conditional implantable pulse generators, providing a broad range of options to personalize deep brain stimulation therapy for patients with Parkinson’s disease or essential tremor.
In December 2024, electroCore Inc., a United States-based bioelectronic medicine company, completed the acquisition of NeuroMetrix Inc. for an undisclosed consideration. Through this transaction, electroCore seeks to strengthen its wearable neuromodulation offerings for chronic pain by incorporating NeuroMetrix’s Quell® platform and broadening its portfolio of non-invasive bioelectronic therapies. NeuroMetrix Inc. specializes in the development of wearable neuromodulation solutions designed to address chronic pain management.
Major companies operating in the neuromodulation market are Abbott Laboratories, Soterix Medical Inc., Boston Scientific Corporation, Medtronic plc, Synapse Biomedical Inc., Nevro Corp, NeuroPace Inc., LivaNova PLC, NeuroSigma Inc., Neuronetics Inc., Bioness Inc., Aleva Neurotherapeutics S.A., Integer Holdings Corporation, Inspire Medical Systems Inc., Saluda Medical Pty Ltd, Inbrain Neuroelectronics SAS, Pixium Vision SA, Neuromod Devices Limited, Cognito Therapeutics Inc., PathMaker Neurosystems Inc., Dignify Therapeutics Inc., Neuros Medical Inc., Koninklijke Philips N.V., Omron Corporation.
North America was the largest region in the neuromodulation market in 2025. The regions covered in the neuromodulation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the neuromodulation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the neuromodulation market by increasing costs of imported electronic components, implantable biomaterials, microcontrollers, stimulation leads, and precision manufacturing equipment. Hospitals and specialty clinics in North America and Europe are most affected due to reliance on imported high-tech implants, while Asia-Pacific faces higher costs in device exports. These tariffs are increasing treatment costs and slowing adoption rates. However, they are also encouraging domestic production, localized component sourcing, and innovation in cost-efficient neuromodulation device designs.
The neuromodulation market research report is one of a series of new reports that provides neuromodulation market statistics, including neuromodulation industry global market size, regional shares, competitors with a neuromodulation market share, detailed neuromodulation market segments, market trends and opportunities, and any further data you may need to thrive in the neuromodulation industry. This neuromodulation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Neuromodulation refers to the adjustment of nerve activity through electrical or pharmacological means, directly targeting specific areas. It's a reversible method employed to alleviate pain.
The primary technologies in neuromodulation include internal and external methods. Internal neuromodulation involves implanting an electrode near a targeted nerve and administering a low-voltage electric current. Biomaterials used encompass polymeric, metallic, and ceramic materials. These technologies are applied in treating various conditions such as chronic pain, urinary and fecal incontinence, migraine, failed back syndrome, Parkinson’s disease, epilepsy, tremor, depression, and more. They find use across multiple settings including hospitals, clinics, and home healthcare environments.
The neuromodulation market includes revenues earned by entities through sacral nerve stimulation for pelvic disorders and incontinence, deep brain stimulation (DBS) treatment for Parkinson's disease, and spinal cord stimulation for ischemic disorders (angina, peripheral vascular disease). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The neuromodulation market size is expected to see rapid growth in the next few years. It will grow to $12.88 billion in 2030 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to increasing adoption of ai-assisted neuromodulation systems, rising demand for home-based neuromodulation therapies, expansion of indications in psychiatric and neurological disorders, growing focus on patient-specific stimulation protocols, continuous technological advancements in biomaterials and device miniaturization. Major trends in the forecast period include increasing adoption of implantable neuromodulation devices, rising use of non-invasive neuromodulation therapies, growing integration of smart and programmable stimulators, expansion of neuromodulation applications beyond pain, enhanced focus on personalized neurotherapy.
Increasing healthcare expenditures are projected to drive the growth of the neuromodulation market in the coming years. Healthcare expenditure encompasses the total funds allocated for health care and related activities, including health services provision, public and private health insurance, health research, and public health initiatives. Rising expenditures support the development and adoption of new therapies and diagnostic methods for neurological disorders, and they also provide additional funding for research into innovative neuromodulation technologies, enhancing their efficacy, safety, and targeting capabilities. For example, in June 2025, according to the Centers for Medicare & Medicaid Services, national health expenditures in 2023 increased by 7.5% to reach $4.9 trillion, or $14,570 per capita, representing 17.6% of the United States gross domestic product. Thus, the rising healthcare expenditure is fueling the growth of the neuromodulation market.
Leading players in the neuromodulation sector are prioritizing the development of next-generation solutions, including advanced implantable pulse generators (IPGs), to enhance therapeutic accuracy, improve patient comfort, and strengthen their competitive positioning. An IPG is a small, battery-powered device implanted beneath the skin commonly in the chest or abdominal area, that delivers controlled electrical stimulation to treat neurological disorders. Ongoing innovations focus on enabling greater personalization, extending battery life, and simplifying implantation procedures. For instance, in July 2023, Boston Scientific Corporation received approval from the U.S. Food and Drug Administration for its Vercise Neural Navigator 5 software with STIMVIEW XT technology, intended for use with the fourth-generation Vercise Genus Deep Brain Stimulation system. The solution supports both rechargeable and non-rechargeable IPGs and accommodates five magnetic resonance-conditional implantable pulse generators, providing a broad range of options to personalize deep brain stimulation therapy for patients with Parkinson’s disease or essential tremor.
In December 2024, electroCore Inc., a United States-based bioelectronic medicine company, completed the acquisition of NeuroMetrix Inc. for an undisclosed consideration. Through this transaction, electroCore seeks to strengthen its wearable neuromodulation offerings for chronic pain by incorporating NeuroMetrix’s Quell® platform and broadening its portfolio of non-invasive bioelectronic therapies. NeuroMetrix Inc. specializes in the development of wearable neuromodulation solutions designed to address chronic pain management.
Major companies operating in the neuromodulation market are Abbott Laboratories, Soterix Medical Inc., Boston Scientific Corporation, Medtronic plc, Synapse Biomedical Inc., Nevro Corp, NeuroPace Inc., LivaNova PLC, NeuroSigma Inc., Neuronetics Inc., Bioness Inc., Aleva Neurotherapeutics S.A., Integer Holdings Corporation, Inspire Medical Systems Inc., Saluda Medical Pty Ltd, Inbrain Neuroelectronics SAS, Pixium Vision SA, Neuromod Devices Limited, Cognito Therapeutics Inc., PathMaker Neurosystems Inc., Dignify Therapeutics Inc., Neuros Medical Inc., Koninklijke Philips N.V., Omron Corporation.
North America was the largest region in the neuromodulation market in 2025. The regions covered in the neuromodulation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the neuromodulation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the neuromodulation market by increasing costs of imported electronic components, implantable biomaterials, microcontrollers, stimulation leads, and precision manufacturing equipment. Hospitals and specialty clinics in North America and Europe are most affected due to reliance on imported high-tech implants, while Asia-Pacific faces higher costs in device exports. These tariffs are increasing treatment costs and slowing adoption rates. However, they are also encouraging domestic production, localized component sourcing, and innovation in cost-efficient neuromodulation device designs.
The neuromodulation market research report is one of a series of new reports that provides neuromodulation market statistics, including neuromodulation industry global market size, regional shares, competitors with a neuromodulation market share, detailed neuromodulation market segments, market trends and opportunities, and any further data you may need to thrive in the neuromodulation industry. This neuromodulation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Neuromodulation refers to the adjustment of nerve activity through electrical or pharmacological means, directly targeting specific areas. It's a reversible method employed to alleviate pain.
The primary technologies in neuromodulation include internal and external methods. Internal neuromodulation involves implanting an electrode near a targeted nerve and administering a low-voltage electric current. Biomaterials used encompass polymeric, metallic, and ceramic materials. These technologies are applied in treating various conditions such as chronic pain, urinary and fecal incontinence, migraine, failed back syndrome, Parkinson’s disease, epilepsy, tremor, depression, and more. They find use across multiple settings including hospitals, clinics, and home healthcare environments.
The neuromodulation market includes revenues earned by entities through sacral nerve stimulation for pelvic disorders and incontinence, deep brain stimulation (DBS) treatment for Parkinson's disease, and spinal cord stimulation for ischemic disorders (angina, peripheral vascular disease). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Neuromodulation Market Characteristics
3. Neuromodulation Market Supply Chain Analysis
4. Global Neuromodulation Market Trends and Strategies
5. Neuromodulation Market Analysis of End Use Industries
7. Global Neuromodulation Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Neuromodulation Total Addressable Market (TAM) Analysis for the Market
9. Neuromodulation Market Segmentation
10. Neuromodulation Market Regional and Country Analysis
11. Asia-Pacific Neuromodulation Market
12. China Neuromodulation Market
13. India Neuromodulation Market
14. Japan Neuromodulation Market
15. Australia Neuromodulation Market
16. Indonesia Neuromodulation Market
17. South Korea Neuromodulation Market
18. Taiwan Neuromodulation Market
19. South East Asia Neuromodulation Market
20. Western Europe Neuromodulation Market
21. UK Neuromodulation Market
22. Germany Neuromodulation Market
23. France Neuromodulation Market
24. Italy Neuromodulation Market
25. Spain Neuromodulation Market
26. Eastern Europe Neuromodulation Market
27. Russia Neuromodulation Market
28. North America Neuromodulation Market
29. USA Neuromodulation Market
30. Canada Neuromodulation Market
31. South America Neuromodulation Market
32. Brazil Neuromodulation Market
33. Middle East Neuromodulation Market
34. Africa Neuromodulation Market
36. Neuromodulation Market Competitive Landscape and Company Profiles
37. Neuromodulation Market Other Major and Innovative Companies
40. Neuromodulation Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Neuromodulation Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses neuromodulation market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for neuromodulation? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The neuromodulation market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Technology: Internal Neuromodulation; External Neuromodulation (Non-invasive)2) By Biomaterial: Polymeric Biomaterial; Metallic Biomaterial; Ceramic Biomaterial
3) By Application: Chronic Pain; Urinary And Fecal Incontinence; Migraine; Failed Back Syndrome; Parkinson Disease; Epilepsy; Tremor; Depression; Other Applications
4) By End-User: Hospitals; Clinics; Home Healthcare
Subsegments:
1) By Internal Neuromodulation: Implantable Devices; Intrathecal Drug Delivery Systems2) By External Neuromodulation (Non-invasive): Transcranial Magnetic Stimulation (TMS); Transcranial Direct Current Stimulation (tDCS); Transcutaneous Electrical Nerve Stimulation (TENS); Peripheral Nerve Stimulation (PNS)
Companies Mentioned: Abbott Laboratories; Soterix Medical Inc.; Boston Scientific Corporation; Medtronic plc; Synapse Biomedical Inc.; Nevro Corp; NeuroPace Inc.; LivaNova PLC; NeuroSigma Inc.; Neuronetics Inc.; Bioness Inc.; Aleva Neurotherapeutics S.A.; Integer Holdings Corporation; Inspire Medical Systems Inc.; Saluda Medical Pty Ltd; Inbrain Neuroelectronics SAS; Pixium Vision SA; Neuromod Devices Limited; Cognito Therapeutics Inc.; PathMaker Neurosystems Inc.; Dignify Therapeutics Inc.; Neuros Medical Inc.; Koninklijke Philips N.V.; Omron Corporation
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Neuromodulation market report include:- Abbott Laboratories
- Soterix Medical Inc.
- Boston Scientific Corporation
- Medtronic plc
- Synapse Biomedical Inc.
- Nevro Corp
- NeuroPace Inc.
- LivaNova PLC
- NeuroSigma Inc.
- Neuronetics Inc.
- Bioness Inc.
- Aleva Neurotherapeutics S.A.
- Integer Holdings Corporation
- Inspire Medical Systems Inc.
- Saluda Medical Pty Ltd
- Inbrain Neuroelectronics SAS
- Pixium Vision SA
- Neuromod Devices Limited
- Cognito Therapeutics Inc.
- PathMaker Neurosystems Inc.
- Dignify Therapeutics Inc.
- Neuros Medical Inc.
- Koninklijke Philips N.V.
- Omron Corporation
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 8.45 Billion |
| Forecasted Market Value ( USD | $ 12.88 Billion |
| Compound Annual Growth Rate | 11.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 25 |
